Astellas shuffles top management amid push to reshape strategically

New CEO Naoki Okamura will take the reins as Astellas seeks to execute on a strategic plan that will reduce reliance on Xtandi in favor of other innovative medicines, including several in new modalities, by the end of the decade.

Okamura’s promotion will occur as Astellas Pharma Inc. (Tokyo:4503) advances a pipeline that includes a potentially first-in-class CLDN18.2 inhibitor at the registration stage for gastric cancer. The company has also recently named targeted protein degradation as a priority, adding to its array of newer modalities and techniques to treat disorders in a range of therapeutic areas...